ArriVent BioPharma reported its second quarter 2026 financial results. Quarterly financial results provide key data on company performance and outlook.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | 1 | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 150.39 | 218.86 | 312.82 | 373.12 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 159.97 | 226.98 | 332.90 | 394.17 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 4.53 | 3.78 | 5.93 | 2.22 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 11.62 | 17.27 | 25.95 | 27.84 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | — | ‡‡‡ |
| Earnings | — | — | ‡‡‡ |
| Book Value | — | — | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (41.89) | (39.58) | — | — |
—
|
| ’25 | (68.01) | (26.12) | (35.80) | (30.66) |
(160.59)
|
| ’24 | (18.63) | (19.09) | (16.34) | (16.15) |
(70.21)
|
| ’23 | (16.88) | (8.61) | (15.44) | (14.91) |
(55.84)
|
| ’22 | — | — | — | (43.63) |
(43.63)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (41.89) | (39.58) | — | — |
—
|
| ’25 | (68.01) | (26.12) | (35.80) | (30.66) |
(160.59)
|
| ’24 | (18.63) | (19.09) | (16.34) | (16.15) |
(70.21)
|
| ’23 | (16.88) | (8.61) | (15.44) | (14.91) |
(55.84)
|
| ’22 | — | — | — | (43.63) |
(43.63)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.96) | (1.05) | — | — |
—
|
| ’25 | (1.90) | (0.90) | (0.83) | (0.78) |
(4.32)
|
| ’24 | (0.70) | (0.65) | (0.61) | (0.61) |
(2.56)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 14.35 | 15.47 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | — | 36.37 | 29.71 | — | — | — |
High Price
|
| — | — | — | — | — | — | 40 | 40 | 52 | 77 | — | — | — |
Employees
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Gross Margin
|
| — | — | — | — | — | ‡‡‡‡‡ | (36.91) | (69.33) | (80.49) | (166.31) | — | — | — |
EBT
|
| — | — | — | — | — | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | — | — | — | — | ‡‡‡‡‡ | (36.91) | (69.33) | (80.49) | (166.31) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | — | — | — | — | — | (3.03) | — | — | — |
Depreciation
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | — | — | — | (32.38) | (2.56) | (4.32) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | (34.17) | (26.08) | (2.23) | (4.18) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | (34.17) | (26.08) | (2.23) | (4.18) | — | — | — |
Free CF/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 136.62 | 70.67 | 8.19 | 7.99 | — | — | — |
Book Value/Sh
|
| — | — | — | — | — | ‡‡‡‡‡ | 1.28 | 2.14 | 31.47 | 38.46 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | (43.63) | (55.84) | (70.21) | (160.59) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | — | — | — | ‡‡‡‡‡ | (43.63) | (55.84) | (70.21) | (160.59) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | 174.26 | 148.34 | 209.71 | 306.95 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | (163.37) | (150.39) | (218.86) | (312.82) | — | — | — |
Net Debt
|
| — | — | — | — | — | ‡‡‡‡‡ | 174.46 | 151.30 | 257.65 | 307.22 | — | — | — |
Sh' Equity
|
| — | — | — | — | — | ‡‡‡ | (32.68%) | (40.08%) | (36.75%) | (54.70%) | — | — | — |
ROA
|
| — | — | — | — | — | ‡‡‡‡‡ | (207.99%) | (5,134.22%) | (151.95%) | 0.00% | — | — | — |
ROIC
|
| — | — | — | — | — | ‡‡‡ | 55.19% | 58.19% | (154.10%) | (58.88%) | — | — | — |
ROE
|
ArriVent BioPharma (AVBP) is a classic high-risk, high-reward biotech bet in oncology, burning cash aggressively with no revenue until 2025 while building a solid 2-3 year runway from its $220 million net cash pile. Massive 2024 dilution from an IPO or merger spiked shares outstanding 1,370%, slashing EPS and book value, but fueled clinical ramps amid escalating losses from $52 million in 2021 to $81 million last year—par for the course in pre-commercial biotechs chasing breakthroughs.
Analysts see fireworks ahead: tiny 2025-2026 revenues exploding to $51 million in 2027, with price targets implying 38-109% upside from recent levels, fueled by hot oncology trends like ADCs and potential Phase 3 catalysts. Valuation looks speculative at negative PEs but juicy if approvals hit, echoing past winners like Seagen’s blockbuster buyout.
Yet risks scream caution—90% Phase 2 failure rates, zero insider buys, one big sell-off, and macro biotech winters could dilute further or tank shares. For patient investors, AVBP could multi-bag on milestones; watch 2026 readouts closely. [Read the full analysis]
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.